Blood test flags lung cancer relapse months before scans show it

After surgery for lung cancer, patients wait between periodic imaging scans, and for many of them the wait is where the fear sits. A tumor can be too small to appear on an image while it already sheds DNA into the blood. A study published in The Journal of Molecular Diagnostics reports that a blood test can catch that signal first: a positive result detected microscopic recurrence months before scans showed a physical tumor.

Non-small-cell lung cancer, or NSCLC, is the most common type of lung cancer and remains the main cause of cancer death. Small tumors at stages I and II are usually removed surgically, and survival rates are reasonably high. Even so, recurrence rates in stage I range between 5% and 19%, and imaging follow-up remains the standard of care. The method the team tested works differently from a scan: it looks at genetic material. Tumor DNA comes from a pathology sample, and normal DNA comes from the buffy coat, the layer of white blood cells separated from a blood sample. Both undergo whole-genome sequencing, a full reading of the genetic code, to build a signature unique to the patient. At each follow-up, the circulating tumor DNA in the plasma is sequenced and compared with that signature by an artificial intelligence pattern-recognition algorithm. The sequencing technology was developed by Asaf Zviran of C2i Genomics in New York.

The study followed patients across their treatment with serial blood draws. Harvey Pass, a cardiothoracic surgeon at NYU Langone Health, says he wants to know as soon as possible if a cancer has returned, since even the earliest-stage patients face that risk. Matija Snuderl, a pathologist at the same institution, calls this minimal residual disease testing, meaning the search for the small amount of cancer left after treatment, and describes it as "a fundamental shift in postoperative care." The paper's title names stage IA lung adenocarcinoma specifically. The account gives no number of patients and no sensitivity or specificity figure, so the claims of high accuracy rest for now on the authors' own description of their results.

The first people to gain would be patients in surveillance after early-stage surgery, and the clinicians who follow them. According to the investigators, the test could identify high- or low-risk patients far earlier, guide targeted treatment for those with detectable residual disease, and spare those with clear results from unnecessary overtreatment and toxicity. Restarting treatment while the disease burden is very low could, in the authors' words, substantially improve long-term outcomes and survival prognosis. The study does not give a date for routine use, nor does it describe how the test would fit into standard follow-up schedules. Until a larger, independently reproduced study reports its accuracy, the change remains a research result for the clinic rather than a replacement for the scan.